welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million
Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.
expertly curated content related to this topic
- Foundazione IRCCS Istituto Nazionale dei TumoriIstituto Nazionale dei Tumori is regarde...
- Lisa A. North, MSLisa Amacker North is a Genetic Counselo...
- Carol Durno, MDDr. Carol Durno, MD, is a paediatric gas...
- Medstar Franklin Square Medical CenterMedstar Franklin Square Medical Center's...
- Jenny JonesJenny was diagnosed with Familial Adenom...
- Familial Adenomatous Polyposis in Pediatrics: Natural History, Emerging Surveillance and Management Protocols, Chemo...Familial adenomatous polyposis (FAP) is ...
- Sue Clark, MDSue Clark trained in medicine at Cambrid...
English
Portuguese